FLOW CYTOMETRY NETWORK FOR BLADDER CANCER

膀胱癌流式细胞术网络

• 批准号: 3548795
• 负责人: RONALD S. WEINSTEIN
• 金额: $ 0.73万
• 依托单位: RUSH UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-09-30 至 1989-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3548795
• 关键词: bladder neoplasm; clinical biomedical equipment; cytodiagnosis; cytogenetics; diagnosis design /evaluation; diagnosis quality /standard; flow cytometry; fluorescent dye /probe; histochemistry /cytochemistry; human subject; immunofluorescence technique; karyotype; monoclonal antibody; neoplasm /cancer diagnosis; preneoplastic state; tissue /cell preparation; tumor antigens; urine

Investigation of flow cytometric (FCM) analysis of urinary bladder barbotage specimens has demonstrated that FCM is useful and practical for monitoring recurrences and response to therapy in bladder carcinoma patients. We believe, however, that before this technology is offered on a nationwide basis, it is essential to optimize and standardize it, taking into account recent cytometric innovations and, especially, advances in the understanding of neoplastic and preneoplastic diseases of the urinary bladder. First, we will develop a method to detect a wider range of urologic neoplasia, particularly low grade papillary and flat preneoplastic lesions without detectable ploidy abnormalities. Potentially, our approach will correct some of the most serious technical drawbacks associated with the current cytochemistry and instrumentation, including unsuitability for fixed cells or cells recovered from voided urine, low resolution and sensitivity for abnormal DNA stemlines, high nonspecific staining of certain cell types, and lack of widespread laboratory acceptance of the technique. We propose to develop a method which will employ simple, widely acceptable cytochemistry and a standard commercially available instrument. However, to determine the optimal combination of cellular parameters for our method, we will also perform sophisticated multiparameter analysis directly comparing three or more fluorescence parameters on the same cells. Finally, our studies will improve the scientific basis of FCM studies by comparing FCM with cytogenetics on the same patients and defining the cellular abnormalities detectable by FCM which are characteristic of the full range of preneoplastic bladder lesions.

膀胱肿瘤的流式细胞术分析 实验结果表明，FCM在检测拟饵鱼中的蛋白质含量方面具有实用价值。 膀胱癌复发及疗效监测 患者 然而，我们认为，在这项技术在一个 在全国范围内，必须优化和规范它， 考虑到最近的细胞计数创新，特别是， 了解泌尿系肿瘤和肿瘤前疾病 膀胱 首先，我们将开发一种方法来检测更广泛的 泌尿系肿瘤，特别是低度乳头状和扁平肿瘤前病变 没有可检测的倍性异常的病变。 潜在地，我们的方法 将纠正一些最严重的技术缺陷， 目前的细胞化学和仪器，包括不适合 固定的细胞或从排泄的尿中回收的细胞，低分辨率， 对异常DNA干细胞的敏感性， 某些细胞类型，缺乏广泛的实验室接受的 法 我们建议开发一种方法， 可接受的细胞化学和标准市售仪器。 然而，为了确定细胞参数的最佳组合， 我们的方法，我们还将进行复杂的多参数分析， 直接比较相同的三个或更多个荧光参数， 细胞 最后，本文的研究将进一步完善FCM的科学基础 通过比较FCM与细胞遗传学对相同患者的研究， 定义FCM可检测的细胞异常， 肿瘤前膀胱病变的全部特征。